Endometrial cancer is the most common gynecological cancer in the developed world, and
it is one of the few cancer types that is becoming more prevalent and leading to more deaths …

Introduction Intrinsic or acquired chemoresistance is a major problem in oncology. Although
highly responsive to chemotherapies such as paclitaxel, most triple negative breast cancer (…

Estrogen receptor 1 (ESR1) mutations have been identified in hormone therapy–resistant
breast cancer and primary endometrial cancer. Analyses in breast cancer suggest that mutant …

This study demonstrates the multiple roles of mutant ER in breast cancer progression, including
constant ER activity and secondary regulatory effects on gene expression and chromatin …

Aneuploidy plays an important role in the development of cancer. Here, we uncovered an
oncogenic role for geminin in mitotic cells. In addition to chromatin, tyrosine phosphorylated …

… were generated using the CRISPR epitope tagging chromatin immunoprecipitation
sequencing method created by Savic and colleagues (23) and previously described in Blanchard …

Ovarian cancer is the first in mortalities among gynecologic cancers in the United States,
often due to late diagnosis and/or acquired platinum-resistant recurrences. This study …

Breast cancer is the second leading cause of cancer-related deaths in women. Triple
negative breast cancer (TNBC) is an aggressive subtype that affects 10–25% mostly African …

Most endometrial cancers express the hormone receptor estrogen receptor alpha (ER) and
are driven by excess estrogen signaling. However, evaluation of the estrogen response in …

Estrogen receptor α (ER) mutations occur in up to 30% of metastatic ER-positive breast cancers.
Recent data has shown that ER mutations impact the expression of thousands of genes …